The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2015 | Overview of a Phase I clinical trial using zanubrutinib (formerly BGB-3111) for the treatment of relapsed CLL
Constantine Tam, MD from Peter MacCallum Cancer Centre & St. Vincent’s Hospital Melbourne, Melbourne, Australia, gives an overview of the new data being presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL, on BGB-3111 (zanubrutinib), a second generation Bruton’s tyrosine kinase (BTK) inhibitor. The data presented were obtained from a Phase I clinical trial, where the drug was well tolerated and demonstrated a good safety profile.
